Literature DB >> 16006002

Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.).

Piero Luigi Almasio1, Mauro Niero, Donato Angioli, Antonio Ascione, Sergio Gullini, Giorgio Minoli, Nadia C Oprandi, Giovan Battista Pinzello, Giorgio Verme, Angelo Andriulli.   

Abstract

BACKGROUND/AIMS: Liver biopsy represents the gold standard to establish a diagnosis in all liver patients, but its current position in chronic viral hepatitis is questioned. We aimed to create a consensus on best practice of use of liver biopsy in the management of chronic HCV infection.
METHODS: We applied the Delphi method to 12 clinical scenarios of chronic HCV infection, to assess the extent of agreement (consensus measurement) and to resolve disagreement (consensus development) on the appropriateness of liver biopsy.
RESULTS: Among 108 chosen hepatologists, 61 (56.5%) accepted to participate to the first-round survey. In four patients the majority of experts (from 61.4 to 86.2%) agreed not to perform liver biopsy; in two cases an equivalent opinion was found, and in the remaining six scenarios the majority of experts would have recommended a biopsy. No expert recommended liver biopsy in all cases, while most agreed for an histological evaluation of 4 to 8 cases. At the second round, 36 experts (59%) submitted ballots. Fifty-four out of 431 (12.6%) original judgments were changed with equal distribution among different scenarios.
CONCLUSIONS: Our survey showed a great divergence of management of similar patients and should provide a stimulus for an evidence-based evaluation of liver histology in chronic HCV infection.

Entities:  

Mesh:

Year:  2005        PMID: 16006002     DOI: 10.1016/j.jhep.2005.02.041

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  The practice of percutaneous liver biopsy in a gastrohepatology day hospital: a retrospective study on 835 biopsies.

Authors:  Giovanni Clemente Actis; Alda Olivero; Marco Lagget; Rinaldo Pellicano; Antonina Smedile; Mario Rizzetto
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

2.  Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

Authors:  Giada Sebastiani; Alessandro Vario; Maria Guido; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

Review 3.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection.

Authors:  Shawky Abdelhamid Fouad; Serag Esmat; Dalia Omran; Laila Rashid; Mohamed H Kobaisi
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 5.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

6.  Evaluation of the need for treatment on 72 subjects with anti-HBe positive chronic hepatitis B.

Authors:  Shima Soleimani Amiri; Shariar Shafaee; Mohammad Reza Hasanjani Roushan; Masomeh Baiani; Mahmoud Hajiahmadi
Journal:  Caspian J Intern Med       Date:  2012

7.  Boceprevir in chronic hepatitis C infection: a perspective review.

Authors:  Antonio Ascione
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

Review 8.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms.

Authors:  Giada Sebastiani
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.